"These preclinical data represent a significant milestone in the development of one of our core pipeline projects," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics. Simultaneously, the data demonstrate the tolerability of both CT-01 candidates, as no treatment-related toxicity was observed. Strong and comparable efficacy was demonstrated in both therapeutic groups (100mg/kg bid and 300mg/kg bid). The in vivo proof-of-concept data confirm the potent antitumor activity of two CT-01 lead compounds in a liver cancer mouse xenograft model and demonstrate that oral administration of these two CT-01 candidates results in complete tumor regression in a Hep 3B2.1-7 mouse model of HCC. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, announces preclinical proof-of-concept data from one of its core pipeline projects designated CT-01, which is focused on the development of TPD therapy for hepatocellular carcinoma (HCC). WROCŁAW, Poland I JanuI Captor Therapeutics S.A. Results support advancement of CT-01 compounds towards IND expected in late 2022.Data confirm strong anticancer activity of two lead compounds in CT-01 program.Podanie Państwa danych osobowych w celach marketingowych jest dobrowolne. Mają Państwo prawo do złożenia skargi do GIODO (UODO), jeżeli uważają Państwo, że przetwarzanie dotyczących Państwa danych osobowych narusza przepisy Ogólnego rozporządzenia o ochronie danych osobowych z dnia 27 kwietnia 2016 roku. Użytkownik ma prawo dostępu do swoich danych oraz prawo do ich poprawiania, usuwania, ograniczania ich przetwarzania, prawo do przekazywania danych, prawo do sprzeciwu, prawo do wycofania zgody w każdej chwili bez wpływu na legalność przetwarzania, które zostało dokonane na podstawie zgody przed jej wycofaniem. Odbiorcą Państwa danych osobowych będą usługodawcy dostarczający naszej firmie rozwiązania techniczne i organizacyjne, a dane nie będą przekazywane do kraju trzeciego/międzynarodowej organizacji i nie będą przetwarzane w sposób zautomatyzowany, w tym w formie profilowania. 1 pkt A przez okres co najmniej 6 lat lub do czasu cofnięcia zgody. Kontakt z inspektorem ochrony danych osobowych: Państwa dane są przetwarzane w celach wynikających z uzasadnionych interesów administratora i marketingu na podstawie przepisów prawa. 1 i 2 rozporządzenia ogólnego o ochronie danych osobowych z dnia 27 kwietnia 2016 r., informuje się, że administratorem danych osobowych jest PMR LTD. I read some testimony about Priest Salami on how he has helped people in bringing back there ex within 48hours i was just thinking if that was real, And decided to call a lady who made a testimony and also dropped her number, So i called her and ask her about Priest Salami she said Priest Salami is a trustworthy man and he is ready to bring back my lover for me, i was just so happy and a little bit relief that my lover will be back to me soon, Then i decided in contacting Priest Salami which i did, And before i could share him my problem he has already told me what i came for, And he said everything will be okay within 24hours that my lover will be back to my arms, So he said he would be casting the spell and that within 24hours my lover would call me, So i hoped so truly before the 24hours i got a call from a man who has left me for the past 1years saying he is sorry and he wants me back, i was happy and i said i also want him back, Then i traveled to Canada to meet him up, And he apologized for what he has done to me now he proposed to marry me and we are both preparing for our wedding soon, All thanks to the great and World best spell caster, Priest Salami His private mail : him directly :+2348143757229 Captor Therapeutics filed a prospectus with the Polish Financial Supervision Authority and announced that it plans to list on the WSE. According to the company’s press release, in his career to date, Shepherd has been responsible for bringing 3 products into clinical trials and has overseen 12 major licensing deals, 3 corporate acquisitions, 6 private financing rounds and 2 initial public offerings. Prior to Captor Therapeutics, he worked at companies in the UK, Australia, the US, France and Switzerland. Tom Shepherd has many years of experience in biotech and pharmaceutical companies. Last week, the company announced that he will assume the role of President of the Management Board at Captor Therapeutics. At that time, he held the position of business development director. He has been appointed as Dr Tom Shepherd.ĭr Shepherd joined Captor in early December 2019. Captor Therapeutics, a biopharmaceutical company working to develop drugs for cancer and autoimmune diseases, has announced the appointment of President of the Management Board.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |